Page 832 - Williams Hematology ( PDFDrive )

806 Part VI: The Erythrocyte Chapter 51: Fragmentation Hemolytic Anemia 807

REFERENCES 33. Sullivan CA, Magann EF, Perry KG Jr, et al: The recurrence risk of the syndrome of
hemolysis, elevated liver enzymes, and low platelets: Subsequent pregnancy outcome
1. Stahnke E: Über das Verhalten der Blutplättchen bei Eklampsie. Zentralbl Gynakol and long term prognosis. Am J Obstet Gynecol 172:125, 1995.
46:391, 1922. 34. van Pampus MG, Wolf H, Mayruhu G, et al: Long-term follow-up in patients with a
2. Pritchard JA, Weisman R Jr, Ratnoff OD, Vosburgh GJ: Intravascular hemolysis, throm- history of (H)ELLP syndrome. Hypertens Pregnancy 20:15, 2001.
bocytopenia and other hematologic abnormalities associated with severe toxemia of 35. Brain MC, Dacie JV, Hourihane DO: Microangiopathic haemolytic anemia: The possi-
pregnancy. N Engl J Med 250:89, 1954. ble role of vascular lesions in pathogenesis. Br J Haematol 8:358, 1962.
3. Goodlin RC, Cotton DB, Haesslein HC: Severe edema-proteinuria-hypertension gesto- 36. Kupers EC, Friedman NB, Lee S, Wolfstein RS: Metastatic hemangiopericytoma asso-
sis. Am J Obstet Gynecol 132:595, 1978. ciated with microangiopathic hemolytic anemia: Review and report of a case. J Am
4. Weinstein L: Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A Geriatr Soc 23:411, 1975.
severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 142:159, 1982. 37. Antman KH, Skarin AT, Mayer RJ, et al: Microangiopathic hemolytic anemia and can-
5. Rahman TM, Wendon J: Severe hepatic dysfunction in pregnancy. Q J Med 95:343, cer: A review. Medicine (Baltimore) 58:377, 1979.
2002. 38. Lohrmann H-P, Adam W, Heymer B, Kubanek B: Microangiopathic hemolytic anemia
6. Rath W, Faridi A, Dudenhausen JW: HELLP syndrome. J Perinat Med 28:249, 2000. in metastatic carcinoma. Report of eight cases. Ann Intern Med 79:368, 1973.
7. Martin JN Jr, Magann EF, Blake PG, et al: Analysis of 454 pregnancies with severe 39. Gordon SG, Cross BA: A factor X-activating cysteine protease from malignant tissue.
preeclampsia/eclampsia HELLP syndrome using the 3-class system of classification. J Clin Invest 67:1665, 1981.
Am J Obstet Gynecol 68:386, 1993. 40. Wahrenbrock M, Borsig L, Le D, et al: Selectin-mucin interactions as a probable molec-
8. Sibai BM, Ramadan MK, Usta I, et al: Maternal morbidity and mortality in 442 preg- ular explanation for the association of Trousseau syndrome with mucinous adenocarci-
nancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). nomas. J Clin Invest 112:853, 2003.
Am J Obstet Gynecol 169:1000, 1993. 41. Lynch EC, Bakken CL, Casey TH, Alfrey CP Jr: Microangiopathic hemolytic anemia in
9. Zusterzeel PLM, Visser W, Blom HJ, et al: Methylenetetrahydrofolate reductase poly- carcinoma of the stomach. Gastroenterology 52:88, 1967.
morphisms in preeclampsia and the HELLP syndrome. Hypertens Pregnancy 19:299, 42. Moake JL: Disseminated intravascular coagulation, in Conn’s Current Therapy, edited
2000. by Rakel RE, p 338. WB Saunders, Philadelphia, 1989.
10. Krauss T, Augustin HG, Osmers R, et al: Activated protein C resistance and factor V 43. Reddy NM, Hall SW, MacKintosh R: Partial thromboplastin time: Prediction of adverse
Leiden in patients with haemolysis, elevated liver enzymes, low platelets syndrome. events and poor prognosis by low abnormal values. Arch Intern Med 159:2706, 1999.
Obstet Gynecol 92:457, 1998. 44. Tripodi A, Chantarangkul V, Martinelli I, et al: A shortened activated partial thromboplas-
11. Bozzo M, Carpani G, Leo L, et al: HELLP syndrome and factor V Leiden. Eur J Obstet tin time is associated with the risk of venous thromboembolism. Blood 104:3631, 2004.
Gynecol Reprod Biol 95:55, 2001. 45. Lippi G, Favaloro EJ: Activated partial thromboplastin time: New tricks for an old
12. Benedetto C, Marozio L, Salton L, et al: Factor V Leiden and factor II G20210A in dogma. Semin Thromb Hemost 34:604, 2008.
preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand 81:1095, 2002. 46. Oleksowicz L, Bhagwati N, DeLeon-Fernandez M: Deficient activity of von
13. Zhou Y, McMaster M, Woo K, et al: Vascular endothelial growth factor ligands and Willebrand’s factor-cleaving protease in patients with disseminated malignancies. Can-
receptors that regulate human cytotrophoblast survival are dysregulated in severe cer Res 59:2244, 1999.
preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J 47. Fontana S, Gerritsen HE, Hovinga JK, et al: Microangiopathic haemolytic anaemia in
Pathol 160:1405, 2002. metastasizing malignant tumours is not associated with a severe deficiency of the von
14. Knerr I, Beinder E, Rascher W: Syncytin, a novel human endogenous retroviral gene in Willebrand factor-cleaving protease. Br J Haematol 113:100, 2001.
human placenta: Evidence for its dysregulation in preeclampsia and HELLP syndrome. 48. Hyun J, Kim HK, Kim JE, et al: Correlation between plasma activity of ADAMTS13
Am J Obstet Gynecol 186:210, 2002. and coagulopathy, and prognosis in disseminated intravascular coagulation. Thromb
15. Levine RJ, Maynard SE, Qian C, et al: Circulating angiogenic factors and the risk of Res 124:75, 2009.
preeclampsia. N Engl J Med 350:672, 2004. 49. Bernardo A, Ball C, Nolasco L, et al: Effects of inflammatory cytokines on the release
16. Widmer M, Villar J, Beniani A, et al: Mapping the theories of preeclampsia and the role and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multim-
of angiogenic factors: A systematic review. Obstet Gynecol 109:168, 2007. ers under flow. Blood 104:100, 2004.
17. Mutter WP, Karumanchi SA: Molecular mechanisms of preeclampsia. Microvasc Res 50. Blake-Haskins JA, Lechleider RJ, Kreitman RJ: Thrombotic microangiopathy with tar-
75:1, 2008. geted cancer agents. Clin Cancer Res 17:5858, 2011.
18. Kim YN, Lee DS, Jeong DH, et al: The relationship of the level of circulating antiangio- 51. Kayatani H, Matsuo K, Ueda Y, et al: Pulmonary tumor thrombotic microangiopathy diag-
genic factors to the clinical manifestations of preeclampsia. Prenat Diagn 29:464, 2009. nosed antemortem and treated with combination chemotherapy. Intern Med 51:2767, 2012.
19. Magann EF, Martin JN Jr: Twelve steps to optimal management of HELLP syndrome. 58. Ellis LD, Westerman MP: Autoimmune hemolytic anemia and cancer. JAMA 193:962,
Clin Obstet Gynecol 42:532, 1999. 1965.
20. Thiagarajah S, Bourgeois FJ, Harbert GM, Caudle MR: Thrombocytopenia in preec- 59. Rose JC, Hufnagel CA, Fries ED, et al: The hemodynamic alterations produced by plas-
lampsia: Associated abnormalities and management principles. Am J Obstet Gynecol tic valvular prosthesis for severe aortic insufficiency in man. J Clin Invest 33:891, 1954.
150:1, 1984. 60. Rodgers BM, Sabiston DC Jr: Hemolytic anemia following prosthetic valve replace-
21. Barton JR, Riely CA, Adamed TA, et al: Hepatic histopathologic condition does not ment. Circulation 39:155, 1969.
correlate with laboratory abnormalities in HELLP syndrome (hemolysis, elevated liver 61. Marsh GW, Lewis SM: Cardiac haemolytic anaemia. Semin Hematol 6:133, 1969.
enzymes, and low platelet count). Am J Obstet Gynecol 167:1538, 1992. 62. Kloster FE: Diagnosis and management of complications of prosthetic heart valves. Am
22. De Boer K, Büller HR, Ten Cate JW, Treffers PE: Coagulation studies in the syndrome J Cardiol 35:872, 1975.
of haemolysis, elevated liver enzymes and low platelets. Br J Obstet Gynaecol 98:42, 63. Iguro Y, Moriyama Y, Yamaoka A, et al: Clinical experience of 473 patients with the
1991. Omnicarbon prosthetic heart valve. J Heart Valve Dis 8:674, 1999.
23. Thorp JM Jr, Gilbert GC II, Moake JL, Bowes WA Jr: von Willebrand factor multimeric 64. Eyster E, Rothchild J, Mychajliw O: Chronic intravascular hemolysis after aortic valve
levels and patterns in patients with severe preeclampsia. Obstet Gynecol 75:163, 1990. replacement. Circulation 44:657, 1971.
24. Lattuada A, Rossi E, Calzarossa C, et al: Mild to moderate reduction of a von Willebrand 65. Crexells C, Aerichide N, Bonny Y, et al: Factors influencing hemolysis in valve prosthe-
factor cleaving protease (ADAMTS13) in pregnant women with HELLP microangio- sis. Am Heart J 84:161, 1972.
pathic syndrome. Haematologica 88:1029, 2003. 66. Demirsoy E, Yilmaz O, Sirin G, et al: Hemolysis after mitral valve repair; a report of five
25. Molvarec A, Rigo J, Boze T, et al: Increased plasma von Willebrand factor antigen levels cases and literature review. J Heart Valve Dis 17:24, 2008.
but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preec- 67. Kubo T, Kitaoka H, Terauchi Y, et al: Hemolytic anemia in a patient with hypertrophic
lampsia. Thromb Haemost 101:305, 2009. obstructive cardiomyopathy. J Cardiol 55:125, 2010.
26. Moake JL: Thrombotic microangiopathies. N Engl J Med 347:589, 2002. 68. Garcia MJ, Vandervoort P, Stewart WJ, et al: Mechanisms of hemolysis with mitral pros-
27. Thomas EA, Copplestone JA, Dubbins PA, Friend JR: The radiologist cries “HELLP”! Br thetic regurgitation. J Am Coll Cardiol 27:399, 1996.
J Radiol 64:964, 1991. 69. Skoularigis J, Essop MR, Skudicky D, et al: Frequency and severity of intravascular
28. Rehberg JF, Briery CM, Hudson WT, et al: Thrombotic thrombocytopenic purpura hemolysis after left-sided cardiac valve replacement with Medtronic Hall and St. Jude
masquerading as hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome Medical prostheses, and influence of prosthetic type, position, size and number. Am J
in late pregnancy. Obstet Gynecol 108:817, 2006. Cardiol 71:587, 1993.
29. Fonseca JE, Mendez F, Catano C. Dexamethasone treatment does not improve the out- 70. Chang H, Lin FY, Hung CR, Chu SH: Chronic intravascular hemolysis after valvular
come of women with HELLP syndrome: A double-blind, placebo-controlled, random- surgery. J Formos Med Assoc 89:880, 1990.
ized clinical trial. Am J Obstet Gynecol 193:1591, 2005. 71. Yacoub MH, Keeling DH: Chronic haemolysis following insertion of ball valve prosthe-
30. Burwick RM, Feinberg BB: Eculizumab for the treatment of preeclampsia/HELLP syn- ses. Br Heart J 30:676, 1968.
drome. Placenta 34:201, 2012. 72. Falk RH, Mackinnon J, Wainscoat J, et al: Intravascular haemolysis after valve replace-
31. Reubinoff BE, Schenker JG: HELLP syndrome—a syndrome of hemolysis, elevated ment: Comparative study between Starr-Edwards (ball valve) and Bjork-Shiley (disc
liver enzymes and low platelet count—complicating preeclampsia-eclampsia. Int J valve) prosthesis. Thorax 34:746, 1979.
Gynaecol Obstet 36:95, 1991. 73. Febres-Roman PR, Bourg WC, Crone RA, et al: Chronic intravascular hemolysis
32. Harms K, Rath W, Herting E, Kuhn W: Maternal hemolysis, elevated liver enzymes, low after aortic valve replacement with Ionescu-Shiley xenograft: Comparative study with
platelet count, and neonatal outcome. Am J Perinatol 12:1, 1995. Bjork-Shiley prosthesis. Am J Cardiol 46:735, 1980.

Kaushansky_chapter 51_p0801-0008.indd 807 9/17/15 2:42 PM